Anavex Files U.S. IND for Alzheimer's Drug Blarcamesine, Paving Way for Trials
AVXL sits 22% above its 52-week low of $2.255.
Summary
Anavex filed a U.S. IND for blarcamesine in early Alzheimer's, a key step toward U.S. clinical trials and FDA discussions. ADME studies are set to begin in Q3 2026, with DDI dosing already underway. This follows the Q2 loss of $5.3M and $127.4M cash runway reported last week, which funds operations into mid-late FY2028. The IND filing marks a concrete regulatory milestone for the company's lead asset, potentially derisking the U.S. development path amid ongoing boardroom turmoil and Nasdaq compliance issues.
At the time of this announcement, AVXL was trading at $2.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $254.8M. The 52-week trading range was $2.26 to $12.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.